Connect with us

Headlines

FDA Approves B+L Eye Surgery Drug

It treats postoperative inflammation and pain.

mm

Published

on

BRIDGEWATER, NJ — Bausch + Lomb announced that the U.S. Food and Drug Administration has approved Lotemax SM 0.38%, a gel formulation for the treatment of postoperative inflammation and pain following ocular surgery.

Compared to Lotemax Gel 0.5%, Lotemax SM (loteprednol etabonate ophthalmic gel) delivers a submicron particle size for faster drug dissolution in tears, according to a press release from the company. Lotemax SM also provides two times greater penetration to the aqueous humor compared to Lotemax Gel.

“With the FDA approval of LOTEMAX SM, physicians can now prescribe to their patients our most advanced loteprednol etabonate formulation to date, indicated for the treatment of postoperative inflammation and pain following ocular surgery,” said Joe Gordon, U.S. president, Bausch + Lomb.

“Since Bausch + Lomb introduced the first formulation of loteprednol etabonate more than 20 years ago, we have continued to advance formulations that meet the changing needs of our patients. We are planning to make LOTEMAX SM available as a new treatment option for patients by April 2019.”

“Patients undergoing ocular surgery, including cataract surgery, often experience inflammation that needs to be treated. This inflammation can be painful and result in serious complications,” said Dr. Marguerite McDonald, ophthalmologist and clinical professor of ophthalmology, New York University School of Medicine.

“In two clinical trials, LOTEMAX SM was significantly more effective than vehicle in completely resolving ocular inflammation and pain following cataract surgery, one of the most common operations performed in the United States.

Advertisement

“LOTEMAX SM provides proven efficacy, efficient penetration, and less frequent dosing compared to LOTEMAX GEL, and the tolerability profile that we have come to expect from the loteprednol etabonate molecule. Together these factors support LOTEMAX SM as an important new option for many of my patients who require treatment for inflammation and pain following ocular surgery.”

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

SPONSORED VIDEO

Crizal® Sapphire™ HR: Invisible Shield of Protection

Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR, the latest and most advanced product in the Crizal No-Glare range, is now widely available across lab networks and through all major managed vision care providers. Crizal Sapphire HR is available with Essilor’s advanced lens designs such as Varilux® progressive lenses and Eyezen® enhanced single vision lenses. Click here to learn more. *External laboratory tests and internal technical tests – 2020. Compared to the competitor most known lens-brands by consumers (2019 external brand tracking in 11 countries). The word ’overall’ refers to anti-reflective coatings important criteria, ranked through an external quantitative consumer study – 2019.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular